Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

Summary

The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis

Timeline

Start

2022-02-15

Primary completion

2027-02-26

Completion

2028-12-05

Publications

• Almquist J, Chia YL, Tummala R, Bertagnolli L, Jayne D, Tang W, Lindholm C. Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis. Clin Pharmacol Ther. 2026 May 22. doi: 10.1002/cpt.70307. Online ahead of print.
• Avasare R, Drexler Y, Caster DJ, Mitrofanova A, Jefferson JA. Management of Lupus Nephritis: New Treatments and Updated Guidelines. Kidney360. 2023 Oct 1;4(10):1503-1511. doi: 10.34067/KID.0000000000000230.

Drugs

Indications